Highlights
KLSE: INIX (0094)       INIX TECHNOLOGIES HOLDINGS BHD ACE : Technology
Last Price Today's Change   Day's Range   Trading Volume
0.365   0.00 (0.00%)  0.35 - 0.375  29,399,500
Trade this stock and receive a FREE I3investor T-shirt after 5 trades. Find out more.

Financials


Market Cap: 170 Million

Market Cap 170 Million
NOSH 467 Million

Latest Audited Result:  31-Jan-2020

Latest Audited Result: 31-Jan-2020
Announcement Date 30-Jun-2020
Next Audited Result: 31-Jan-2021
Est. Ann. Date: 30-Jun-2021
Est. Ann. Due Date: 30-Jul-2021

Latest Quarter:  31-Oct-2020 [#3]

Latest Quarter: 31-Oct-2020 [#3]
Announcement Date 28-Dec-2020
Next Quarter: 31-Jan-2021
Est. Ann. Date: 19-May-2021
Est. Ann. Due Date: 01-Apr-2021
QoQ | YoY   -475.46%  |    -581.51%

Annual (Unaudited) ( EPS: -0.59, P/E: -62.20 )

Revenue | NP to SH 8,049  |  -2,738
RPS | P/RPS 1.73 Cent  |  21.16
EPS | P/E | EY -0.59 Cent  |  -62.20  |  -1.61%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.05  |  7.26
YoY   82.14%
NP Margin | ROE -41.73%  |  -11.66%
F.Y. | Ann. Date 31-Jan-2020  |  19-May-2020

T4Q Result ( EPS: 0.46, P/E: 80.00 )

Revenue | NP to SH 3,638  |  2,129
RPS | P/RPS 0.78 Cent  |  46.81
EPS | P/E | EY 0.46 Cent  |  80.00  |  1.25%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.08  |  4.67
QoQ | YoY   -24.53%  |    143.87%
NP Margin | ROE 41.15%  |  5.83%
F.Y. | Ann. Date 31-Oct-2020  |  28-Dec-2020

Annualized Result ( EPS: -0.28, P/E: -131.14 )

Revenue | NP to SH 2,694  |  -1,298
RPS | P/RPS 0.58 Cent  |  63.20
EPS | P/E | EY -0.28 Cent  |  -131.14  |  -0.76%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -113.60%  |    73.94%
NP Margin | ROE -55.86%  |  -3.56%
F.Y. | Ann. Date 31-Oct-2020  |  28-Dec-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Jan-2021 28-Dec-2020 31-Oct-2020 3 2,021 -1,129 -1,129 -974 - 36,506 - % -55.86% -2.67% 402,944 0.50 0.43 -0.24 -0.21 0.00 0.00 0.0906 0.08   -220.39%   83.25% 30-Oct-2020 0.20 39.88 -82.74 2.21 -1.21% 0.00% 28-Dec-2020 0.255 50.84 -105.49 2.81 -0.95% 0.00%
31-Jan-2021 07-Oct-2020 31-Jul-2020 2 1,259 -439 -439 -304 - 23,174 - % -34.87% -1.31% 298,255 0.42 0.27 -0.10 -0.07 0.00 0.00 0.0777 0.05   8.43%   94.64% 30-Jul-2020 0.125 29.61 -122.64 1.61 -0.82% 0.00% 07-Oct-2020 0.225 53.30 -220.75 2.90 -0.45% 0.00%
31-Jan-2021 30-Jun-2020 30-Apr-2020 1 630 -493 -493 -332 - 23,144 - % -78.25% -1.43% 298,254 0.21 0.14 -0.11 -0.07 0.00 0.00 0.0776 0.05   87.87%   80.34% 30-Apr-2020 0.03 14.20 -26.95 0.39 -3.71% 0.00% 30-Jun-2020 0.055 26.04 -49.41 0.71 -2.02% 0.00%
31-Jan-2020 19-May-2020 31-Jan-2020 8,049 -3,359 -3,359 -2,738 - 23,472 - % -41.73% -11.66% 298,254 2.70 1.73 -0.92 -0.59 0.00 0.00 0.0787 0.05   52.91%   -192.21% 31-Jan-2020 0.045 1.67 -4.90 0.57 -20.40% 0.00% 19-May-2020 0.045 1.67 -4.90 0.57 -20.40% 0.00%
31-Jan-2020 31-Dec-2019 31-Oct-2019 3 6,432 -6,260 -6,260 -5,814 - 19,682 - % -97.33% -29.54% 298,225 2.16 1.38 -1.95 -1.25 0.00 0.00 0.0660 0.04   -2.45%   -517.85% 31-Oct-2019 0.055 2.55 -2.82 0.83 -35.45% 0.00% 31-Dec-2019 0.05 2.32 -2.56 0.76 -38.99% 0.00%
31-Jul-2019 01-Oct-2019 31-Jul-2019 2 5,276 -6,186 -6,186 -5,675 - 19,061 - % -117.25% -29.77% 271,140 1.95 1.13 -2.09 -1.22 0.00 0.00 0.0703 0.04   -236.00%   64.84% 31-Jul-2019 0.055 2.83 -2.63 0.78 -38.05% 0.00% 01-Oct-2019 0.055 2.83 -2.63 0.78 -38.05% 0.00%
31-Jul-2019 27-Jun-2019 30-Apr-2019 1 3,885 -2,111 -2,111 -1,689 - 21,630 - % -54.34% -7.81% 263,140 1.48 0.83 -0.64 -0.36 0.00 0.00 0.0822 0.05   -80.26%   -2,383.82% 30-Apr-2019 0.06 4.06 -9.35 0.73 -10.70% 0.00% 27-Jun-2019 0.06 4.06 -9.35 0.73 -10.70% 0.00%
31-Jul-2019 29-Mar-2019 31-Jan-2019 2,724 -1,034 -1,034 -937 - 22,001 - % -37.96% -4.26% 259,140 1.05 0.58 -0.36 -0.20 0.00 0.00 0.0849 0.05   0.43%   -317.91% 31-Jan-2019 0.10 9.51 -27.66 1.18 -3.62% 0.00% 29-Mar-2019 0.075 7.13 -20.74 0.88 -4.82% 0.00%
31-Jul-2019 31-Dec-2018 31-Oct-2018 1 1,422 -946 -946 -941 - 21,975 - % -66.53% -4.28% 259,140 0.55 0.30 -0.36 -0.20 0.00 0.00 0.0848 0.05   94.17%   -27.16% 31-Oct-2018 0.07 12.76 -19.28 0.83 -5.19% 0.00% 31-Dec-2018 0.085 15.49 -23.41 1.00 -4.27% 0.00%
31-Jul-2018 23-Oct-2018 31-Jul-2018 9,448 -16,141 -16,142 -16,142 - 15,548 - % -170.85% -103.82% 259,140 3.65 2.02 -5.90 -3.46 0.00 0.00 0.0600 0.03   -23,638.24%   -82.00% 31-Jul-2018 0.065 1.78 -1.04 1.08 -95.83% 0.00% 23-Oct-2018 0.075 2.06 -1.20 1.25 -83.05% 0.00%
31-Jul-2018 29-Aug-2018 30-Apr-2018 3 6,420 1,737 1,737 -68 - 25,564 - % 27.06% -0.27% 255,640 2.51 1.38 -0.03 -0.01 0.00 0.00 0.1000 0.05   -115.81%   97.82% 30-Apr-2018 0.08 3.19 -300.75 0.80 -0.33% 0.00% 29-Aug-2018 0.095 3.78 -357.15 0.95 -0.28% 0.00%
31-Jul-2018 29-Mar-2018 31-Jan-2018 2 3,441 2,063 2,063 430 - 3,904 - % 59.95% 11.01% 37,903 9.08 0.74 1.80 0.09 0.00 0.00 0.1030 0.01   158.11%   195.77% 30-Jan-2018 0.10 1.10 8.81 0.97 11.34% 0.00% 29-Mar-2018 0.07 0.77 6.17 0.68 16.21% 0.00%
31-Jul-2018 29-Dec-2017 31-Oct-2017 1 863 -740 -740 -740 - 4,305 - % -85.75% -17.19% 44,027 1.96 0.18 -0.02 -0.16 0.00 0.00 0.0978 0.01   91.66%   68.24% 31-Oct-2017 0.075 3.83 -4.46 0.77 -22.41% 0.00% 29-Dec-2017 0.13 6.63 -7.73 1.33 -12.93% 0.00%
31-Jul-2017 29-Sep-2017 31-Jul-2017 4 5,232 -8,869 -8,869 -8,869 - 3,095 - % -169.51% -286.50% 24,166 21.65 1.12 -0.37 -1.90 0.00 0.00 0.1281 0.01   -184.17%   -86.91% 31-Jul-2017 0.06 0.28 -0.16 0.47 -611.67% 0.00% 29-Sep-2017 0.08 0.37 -0.22 0.62 -458.75% 0.00%
31-Jul-2017 20-Jul-2017 30-Apr-2017 3 4,184 -3,121 -3,121 -3,121 - 3,286 - % -74.59% -94.96% 24,166 17.31 0.90 -0.13 -0.67 0.00 0.00 0.1360 0.01   -595.10%   40.50% 28-Apr-2017 0.075 0.43 -0.58 0.55 -172.20% 0.00% 20-Jul-2017 0.065 0.38 -0.50 0.48 -198.69% 0.00%
31-Jul-2017 04-Apr-2017 31-Jan-2017 2 2,148 -655 -655 -449 - 6,375 - % -30.49% -7.04% 44,027 4.88 0.46 -2.71 -0.10 0.00 0.00 0.1448 0.01   80.73%   80.72% 31-Jan-2017 0.08 1.64 -7.84 0.55 -12.75% 0.00% 04-Apr-2017 0.09 1.84 -8.83 0.62 -11.33% 0.00%
31-Jul-2017 28-Mar-2017 31-Oct-2016 1 103 -2,688 -2,688 -2,330 - 34,043 - % -2,609.71% -6.84% 458,194 0.02 0.02 -0.06 -0.50 0.00 0.00 0.0743 0.07   50.90%   -2,257.41% 31-Oct-2016 0.08 355.88 -15.73 1.08 -6.36% 0.00% 28-Mar-2017 0.085 378.12 -16.72 1.14 -5.98% 0.00%
31-Jul-2016 28-Sep-2016 31-Jul-2016 4 3,738 -4,738 -4,745 -4,745 - 30,676 - % -126.94% -15.47% 416,228 0.90 0.80 -1.14 -1.02 0.00 0.00 0.0737 0.07   9.53%   -10,684.09% 29-Jul-2016 0.055 6.12 -4.82 0.75 -20.73% 0.00% 28-Sep-2016 0.095 10.58 -8.33 1.29 -12.00% 0.00%
31-Jul-2016 28-Jun-2016 30-Apr-2016 3 1,210 -5,238 -5,245 -5,245 - 30,179 - % -433.47% -17.38% 416,269 0.29 0.26 -1.26 -1.12 0.00 0.00 0.0725 0.06   -125.20%   -660.14% 29-Apr-2016 0.045 15.48 -3.57 0.62 -28.00% 0.00% 28-Jun-2016 0.045 15.48 -3.57 0.62 -28.00% 0.00%
31-Jul-2016 31-Mar-2016 31-Jan-2016 2 1,210 -2,329 -2,329 -2,329 - 33,063 - % -192.48% -7.04% 415,892 0.29 0.26 -0.56 -0.50 0.00 0.00 0.0795 0.07   -2,256.48%   -4,334.55% 29-Jan-2016 0.06 20.62 -10.71 0.75 -9.33% 0.00% 31-Mar-2016 0.05 17.19 -8.93 0.63 -11.20% 0.00%
31-Jul-2016 29-Dec-2015 31-Oct-2015 1 1,186 108 108 108 - 7,546 - % 9.11% 1.43% 135,000 0.88 0.25 0.08 0.02 0.00 0.00 0.0559 0.02   345.45%   115.93% 30-Oct-2015 0.135 15.37 168.75 2.42 0.59% 0.00% 29-Dec-2015 0.065 7.40 81.25 1.16 1.23% 0.00%
31-Jul-2015 30-Sep-2015 31-Jul-2015 4 5,230 -42 -44 -44 - 8,096 - % -0.84% -0.54% 146,666 3.57 1.12 -0.03 -0.01 0.00 0.00 0.0552 0.02   93.62%   96.80% 31-Jul-2015 0.165 4.63 -550.00 2.99 -0.18% 0.00% 30-Sep-2015 0.15 4.21 -500.00 2.72 -0.20% 0.00%
31-Jul-2015 08-Jul-2015 30-Apr-2015 3 3,077 -690 -690 -690 - 6,969 - % -22.42% -9.90% 138,000 2.23 0.66 -0.50 -0.15 0.00 0.00 0.0505 0.01   -1,354.55%   20.23% 30-Apr-2015 0.165 7.40 -33.00 3.27 -3.03% 0.00% 08-Jul-2015 0.13 5.83 -26.00 2.57 -3.85% 0.00%
31-Jul-2015 30-Mar-2015 31-Jan-2015 2 2,414 55 55 55 - 7,686 - % 2.28% 0.72% 137,500 1.76 0.52 0.04 0.01 0.00 0.00 0.0559 0.02   108.11%   102.80% 30-Jan-2015 0.165 9.40 412.50 2.95 0.24% 0.00% 30-Mar-2015 0.17 9.68 425.00 3.04 0.24% 0.00%
31-Jul-2015 17-Dec-2014 31-Oct-2014 1 307 -678 -678 -678 - 7,001 - % -220.85% -9.68% 138,367 0.22 0.07 -0.49 -0.15 0.00 0.00 0.0506 0.01   50.62%   37.34% 31-Oct-2014 0.14 63.10 -28.57 2.77 -3.50% 0.00% 17-Dec-2014 0.085 38.31 -17.35 1.68 -5.76% 0.00%
31-Jul-2014 30-Sep-2014 31-Jul-2014 4 4,950 -1,373 -1,373 -1,373 - 7,697 - % -27.74% -17.84% 138,686 3.57 1.06 -0.99 -0.29 0.00 0.00 0.0555 0.02   -58.73%   -1,207.26% 31-Jul-2014 0.17 4.76 -17.17 3.06 -5.82% 0.00% 30-Sep-2014 0.165 4.62 -16.67 2.97 -6.00% 0.00%
31-Jul-2014 19-Jun-2014 30-Apr-2014 3 2,374 -865 -865 -865 - 8,259 - % -36.44% -10.47% 139,516 1.70 0.51 -0.62 -0.19 0.00 0.00 0.0592 0.02   56.02%   2.92% 30-Apr-2014 0.19 11.17 -30.65 3.21 -3.26% 0.00% 19-Jun-2014 0.175 10.28 -28.23 2.96 -3.54% 0.00%
31-Jul-2014 31-Mar-2014 31-Jan-2014 2 638 -1,967 -1,967 -1,967 - 7,156 - % -308.31% -27.49% 139,503 0.46 0.14 -1.41 -0.42 0.00 0.00 0.0513 0.02   -81.79%   -114.04% 30-Jan-2014 0.195 42.64 -13.83 3.80 -7.23% 0.00% 31-Mar-2014 0.195 42.64 -13.83 3.80 -7.23% 0.00%
31-Jul-2014 30-Dec-2013 31-Oct-2013 1 94 -1,082 -1,082 -1,082 - 6,466 - % -1,151.06% -16.73% 125,813 0.07 0.02 -0.86 -0.23 0.00 0.00 0.0514 0.01   -972.58%   -15.23% 31-Oct-2013 0.16 214.15 -18.60 3.11 -5.38% 0.00% 30-Dec-2013 0.185 247.61 -21.51 3.60 -4.65% 0.00%
31-Jul-2013 25-Sep-2013 31-Jul-2013 4 4,669 124 124 124 - 7,319 - % 2.66% 1.69% 121,999 3.83 1.00 0.10 0.03 0.00 0.00 0.0600 0.02   113.92%   12.73% 31-Jul-2013 0.14 3.66 137.74 2.33 0.73% 0.00% 25-Sep-2013 0.165 4.31 162.34 2.75 0.62% 0.00%
31-Jul-2013 20-Jun-2013 30-Apr-2013 3 2,112 -891 -891 -891 - 6,618 - % -42.19% -13.46% 127,285 1.66 0.45 -0.70 -0.19 0.00 0.00 0.0520 0.01   3.05%   -1,257.14% 30-Apr-2013 0.145 8.74 -20.71 2.79 -4.83% 0.00% 20-Jun-2013 0.095 5.73 -13.57 1.83 -7.37% 0.00%
31-Jul-2013 26-Mar-2013 31-Jan-2013 2 1,080 -919 -919 -919 - 6,521 - % -85.09% -14.09% 125,890 0.86 0.23 -0.73 -0.20 0.00 0.00 0.0518 0.01   2.13%   -2,055.32% 31-Jan-2013 0.145 16.90 -19.86 2.80 -5.03% 0.00% 26-Mar-2013 0.15 17.48 -20.55 2.90 -4.87% 0.00%
31-Jul-2013 28-Dec-2012 31-Oct-2012 1 8 -939 -939 -939 - 6,547 - % -11,737.50% -14.34% 126,891 0.01 0.00 -0.74 -0.20 0.00 0.00 0.0516 0.01   -953.64%   -689.08% 31-Oct-2012 0.13 2,061.99 -17.57 2.52 -5.69% 0.00% 28-Dec-2012 0.14 2,220.61 -18.92 2.71 -5.29% 0.00%
31-Jul-2012 27-Sep-2012 31-Jul-2012 4 5,181 110 110 110 - 7,211 - % 2.12% 1.53% 122,222 4.24 1.11 0.09 0.02 0.00 0.00 0.0590 0.02   42.86%   64.18% 31-Jul-2012 0.12 2.83 133.33 2.03 0.75% 0.00% 27-Sep-2012 0.14 3.30 155.56 2.37 0.64% 0.00%
31-Jul-2012 28-Jun-2012 30-Apr-2012 3 3,354 77 77 77 - 7,533 - % 2.30% 1.02% 128,333 2.61 0.72 0.06 0.02 0.00 0.00 0.0587 0.02   63.83%   133.62% 30-Apr-2012 0.12 4.59 200.00 2.04 0.50% 0.00% 28-Jun-2012 0.12 4.59 200.00 2.04 0.50% 0.00%
31-Jul-2012 30-Mar-2012 31-Jan-2012 2 2,101 47 47 47 - 6,380 - % 2.24% 0.74% 117,500 1.79 0.45 0.04 0.01 0.00 0.00 0.0543 0.01   139.50%   1,040.00% 31-Jan-2012 0.08 4.47 200.00 1.47 0.50% 0.00% 30-Mar-2012 0.12 6.71 300.00 2.21 0.33% 0.00%
31-Jul-2012 30-Dec-2011 31-Oct-2011 1 900 -119 -119 -119 - 6,295 - % -13.22% -1.89% 118,999 0.76 0.19 -0.10 -0.03 0.00 0.00 0.0529 0.01   -277.61%   -164.44% 31-Oct-2011 0.06 7.93 -60.00 1.13 -1.67% 0.00% 30-Dec-2011 0.06 7.93 -60.00 1.13 -1.67% 0.00%
31-Jul-2011 30-Sep-2011 31-Jul-2011 4 4,424 67 67 67 - 6,018 - % 1.51% 1.11% 493,333 3.96 0.95 0.06 0.01 0.00 0.00 0.0539 0.01   129.26%   -84.84% 29-Jul-2011 0.06 1.51 100.00 1.11 1.00% 0.00% 30-Sep-2011 0.06 1.51 100.00 1.11 1.00% 0.00%
31-Jul-2011 21-Jun-2011 30-Apr-2011 3 3,209 -229 -229 -229 - 5,873 - % -7.14% -3.90% 114,499 2.80 0.69 -0.20 -0.05 0.00 0.00 0.0513 0.01   -4,480.00%   -158.57% 29-Apr-2011 0.08 2.85 -40.00 1.56 -2.50% 0.00% 21-Jun-2011 0.08 2.85 -40.00 1.56 -2.50% 0.00%
31-Jul-2011 31-Mar-2011 31-Jan-2011 2 2,019 -5 -5 -5 - 5,996 - % -0.25% -0.08% 112,500 1.79 0.43 0.00 0.00 0.00 0.00 0.0533 0.01   88.89%   -102.12% 31-Jan-2011 0.08 4.46 -1,800.00 1.50 -0.06% 0.00% 31-Mar-2011 0.07 3.90 -1,575.00 1.31 -0.06% 0.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Analyze this stock with MQ Trader system
  13 people like this.
 
Bemillion .Steadybomb..you re really naive. If you do not undertstand to read english do not bother to interpret it on behalf. You re wrong and misleading.

Extract fm attachment.

..iNix's registration with NPRA is essential for the *distribution* of vaccine in Malaysia. Malaysia government has to ensure that only vaccines which meet the MoH's requirements will be registered and used in Malaysia. This evaluation process is made by Product Evaluation Committee of NPRA and drugs control authority for approval
before the Covid-19 vaccine can be used in Malaysia.
....

Where does it says Inix role is only to do with clinical trials as what you think......??????
15/01/2021 2:47 PM
shadowz NPRA will approve Inix application very soon, then supplier agreement will be on the way far ahead of other company whom had show documents and shoot up but nothing approval from NPRA
15/01/2021 4:54 PM
STEADYBOMBIBI85 Read the last part. The hint is there “ As and when iNix has received the approval from MoH, iNix would be able to import the vaccine and supply the same to MoH to conduct 3rd Phase Clinical Trial in which it would be fully sponsored by iNix as INIX’s CSR initiative. This first clinical trial in Malaysia is expected to involve approximately 3,000 volunteers.” The “approval” refers to approval to import the vaccine for clinical trial and not approval to market in Malaysia. Otherwise why do you still need to conduct clinical trials when the vaccine is already approved ? Conflicting isn’t it ?
15/01/2021 6:45 PM
Bemillion Shadow remarks are valid.....
15/01/2021 8:34 PM
Bemillion Steadybonn got all mix up mindset and still blurrrr.
Traders please do your own reading and analysis..do not get disillusioned and misrepsentation by Steadtbomb..which is not the steady..but full of vague and blur mindset..

Better for u to be follower and read ppl comments..because u re still blurr....
15/01/2021 8:38 PM
YuHainTeck Naysayers will always be naysayers.....no point arguing with them. They will always see things negatively. In the end....they will be the actual losers.
15/01/2021 9:16 PM
Aurora13 Smart inix play with the grey line and trying to fool many of those not familiar with drug or vaccine approval. Don't take risk of you are unsure.
Somehow steadybombibi has got some good points, read the announcement carefully. Inix is trying to play with words
15/01/2021 10:06 PM
STEADYBOMBIBI85 They are indeed playing around with words
15/01/2021 11:32 PM
Impression If you are in doubt, better to sell all your Inix now. When they have received approval to import and the shares has shot up, you can buy again. Then you will be sure you won't be con by Inix.
15/01/2021 11:53 PM
Aurora13 Good luck to 'approval'' for 'clinical trial'..that is what they use for goreng.
Btw, any of you here can sponsor any support for anything via CSR, aka charity. Nobody will reject. Getting the agmnt is out of story
16/01/2021 12:06 AM
prince11 https://www.facebook.com/204065539746464/posts/1878681532284848/
clinical trials nothing to with Inix la. it is IMBCAMS conducting clinical trials via Clinical Research Malaysia. they already started calling for volunteer.
IMBCAMS collab with Cansino.
if this trials pass. they will receive NPRA approval.
so, government and whichever company interested can purchase this vaccine to fight covid asap
16/01/2021 1:31 AM
prince11 since Pfizer already receive NPRA approval. why no one want to distribute Pfizer?
because logistic cost is high since need to store in very cool temperature. luckily Pfizer will bear the logistic cost for our government.
so, thats why everyone want to buy vaccine from China.
why not distribute Astrazeneca? because it is selling at cost price, non-profit basis to help the poor.
16/01/2021 1:41 AM
char1234 vaccines are showing side effects to some people .....
16/01/2021 5:43 AM
char1234 if the time come, for us to take it....how many of us will willingly take it
.
16/01/2021 5:44 AM
char1234 Inix trading averagely 30plus ct .... good support before it takes a big step to bypass 50
16/01/2021 5:53 AM
char1234 Hv $$, just park here , getting minimum 50 pct rtns is in store
16/01/2021 5:55 AM
char1234 likely to happen this year.. Wait
16/01/2021 5:57 AM
YuHainTeck @char1234......
You are very smart. I totally agree with you.
16/01/2021 7:01 AM
Bemillion Whatever hope inix optimise on this opening..how inix do it leave it to inix expertise mngmt... Next week limit up lol
16/01/2021 7:36 AM
Bemillion .Malaysia, the world’s biggest producer of medical gloves, has been racing to meet skyrocketing demand due to the pandemic.

MARGMA said the lead time to deliver gloves to customers had increased by more than six months even as manufacturers ramped up production to cope with new orders.

Source.The Focus
Disclaimer
16/01/2021 9:50 AM
SamChong https://www.klsescreener.com/v2/news/view/779047
16/01/2021 11:10 AM
Rocket99999 Registration for Covid-19 vaccination to open soon https://newswav.com/A2101_bLJvD7?s=A_brq4wS4
16/01/2021 12:09 PM
Rahim49 Monday gap up
16/01/2021 12:23 PM
Osman65 https://www.express.co.uk/news/world/1384728/Covid-vaccine-latest-side-effects-Pfizer-jab-23-dead-Norway-coronavirus-update
16/01/2021 1:06 PM
Osman65 https://m.malaysiakini.com/news/559182
Monday inix..up..
16/01/2021 1:17 PM
YuHainTeck Nx week Fly.....
16/01/2021 2:58 PM
shadowz Interesting week ahead for Inix indeed
16/01/2021 5:13 PM
shadowz Looking at 50-60-70?
16/01/2021 5:14 PM
Impression Next week will be a great week for Inix. Sky is the limit.
16/01/2021 7:13 PM
Bemillion Yeeah.. the indicators look good in favour of inix
16/01/2021 8:18 PM
YuHainTeck Yes.....indeed...nx week will be a great week for INIX.
16/01/2021 8:46 PM
Robin_Hood388 Hold tight everyone....Fly to the sky !
16/01/2021 9:07 PM
SamChong Fly to the moon would be better lol
16/01/2021 9:40 PM
Briankk Lucky bought 200 lot
16/01/2021 9:59 PM
Bemillion Gud luk brian
16/01/2021 10:16 PM
shadowz Wow should hv buy more yesterday
16/01/2021 10:34 PM
STEADYBOMBIBI85 The chart honestly doesnt look good.
16/01/2021 10:59 PM
Hotstuff mat chart u talking about
16/01/2021 11:23 PM
SUNNY123 又疫苗又手套 不懂真与假 ~
17/01/2021 8:24 AM
Valueinvestor Glove maybe still 做戏做全套, but vaccine need verify as these China company also signed mou or moa with other listing company. Need more clarity on this.
17/01/2021 9:37 AM
jonsuk67 Discovered that there are 53 members in a group called BLowSHigh, owner is Edmund. Different group but same purpose. They plotted to badmouth this counter and a few others. Be very very careful.
17/01/2021 10:06 AM
Bemillion Jonsuk67. Tq very much for exposing this vigilante ill intention gp of ppl... Actually already suspected this..and true enough good guy spill over the beans.. TQ at least traders can diffrentiate genuine Inix players and those paid scammers...

Its here all over the place..thats why you re still here when asked if you keep on throwing bad and irrational remarks on Inix stock...genuine player can detect it..thats the answer.... They re on payroll to create misrepresentation and misleading info....

Hahaa caught pants down
17/01/2021 10:23 AM
Bemillion So what u can do?

Just read it, digest it and judge yourself before making trading decisions...just ignore it... The risk vested on own shoulder. Make a wise decision and not to be easily influence by bad mouth scammers
17/01/2021 10:27 AM
Robin_Hood388 https://www.chinapress.com.my/?p=2363665&fbclid=IwAR0Of6xgPrs_OyPuRUY4VGLuszI3WmHJJIggS5oujYDY-V0Bnjks4-3FzjQ
17/01/2021 1:12 PM
SamChong Woohoo...Up Up Up to the sky!!!
17/01/2021 2:25 PM
Bemillion Yes. Inix fighters hold your precious ticket..upgrade fm 3rd class to 1 st class soon ...
17/01/2021 4:24 PM
Valueinvestor Solution and bintai will benefited 1st.
17/01/2021 4:44 PM
SamChong 中國康希諾新冠疫苗在俄羅斯測試 92.5%參與者接種後效果理想

https://www.hk01.com/%E5%8D%B3%E6%99%82%E5%9C%8B%E9%9A%9B/574582/%E4%B8%AD%E5%9C%8B%E5%BA%B7%E5%B8%8C%E8%AB%BE%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97%E5%9C%A8%E4%BF%84%E7%BE%85%E6%96%AF%E6%B8%AC%E8%A9%A6-92-5-%E5%8F%83%E8%88%87%E8%80%85%E6%8E%A5%E7%A8%AE%E5%BE%8C%E6%95%88%E6%9E%9C%E7%90%86%E6%83%B3
17/01/2021 5:27 PM
Bemillion Extraction.

.The new coronary pneumonia (COVID-19) vaccine developed by the Chinese company Cansino Biosciences has launched a phase III clinical trial in Russia. Russian biopharmaceutical company Petrovax said on January 14 that the trial showed that as many as 92.5% of participants had a large number of antibodies.

The company also stated that the trial had no adverse side effects.

Ad5-nCoV vaccine adopts adenovirus vector platform technology. Since September 2020, Phase III clinical trials have been launched in Russia. After this vaccine, Phase III trials have been launched in Mexico and Pakistan


Good for inix
17/01/2021 6:40 PM
YuHainTeck Unlike the Pfizer vaccine....it shouldn't pose any problem when they launch it in Msia on Thursday 21st Jan.
17/01/2021 6:55 PM